MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/europace/euad270

Медицинская библиотека · Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023

Clinical course of hypertrophic cardiomyopathy patients implanted with a transvenous or subcutaneous defibrillator.

Francia Pietro, Ziacchi Matteo, Adduci Carmen, Ammendola Ernesto, Pieragnoli Paolo, De Filippo Paolo, Rapacciuolo Antonio, Rella Valeria, Migliore Federico, Viani Stefano, Musumeci Maria Beatrice, Biagini Elena, Lovecchio Mariolina, Baldini Rossella, Falasconi Giulio, Autore Camillo, Biffi Mauro, Cecchi Franco

СтатьяПеревод в очереди

Аннотация

AIMS: The implantable cardioverter-defibrillator (ICD) is a life-saving therapy in patients with hypertrophic cardiomyopathy (HCM) at risk of sudden cardiac death. Implantable cardioverter-defibrillator complications are of concern. The subcutaneous ICD (S-ICD) does not use transvenous leads and is expected to reduce complications. However, it does not provide bradycardia and anti-tachycardia pacing (ATP). The aim of this study was to compare appropriate and inappropriate ICD interventions, complications, disease-related adverse events and mortality between HCM patients implanted with a S- or transvenous (TV)-ICD.

METHODS AND

RESULTS

Consecutive HCM patients implanted with a S- (n = 216) or TV-ICD (n = 211) were enrolled. Propensity-adjusted cumulative Kaplan-Meier curves and multivariate Cox proportional hazard ratios were used to compare 5-year event-free survival and the risk of events. The S-ICD patients had lower 5-year risk of appropriate (HR: 0.32; 95%CI: 0.15-0.65; P = 0.002) and inappropriate (HR: 0.44; 95%CI: 0.20-0.95; P = 0.038) ICD interventions, driven by a high incidence of ATP therapy in the TV-ICD group. The S- and TV-ICD patients experienced similar 5-year rate of device-related complications, albeit the risk of major lead-related complications was lower in S-ICD patients (HR: 0.17; 95%CI: 0.038-0.79; P = 0.023). The TV- and S-ICD patients displayed similar risk of disease-related complications (HR: 0.64; 95%CI: 0.27-1.52; P = 0.309) and mortality (HR: 0.74; 95%CI: 0.29-1.87; P = 0.521).

CONCLUSION

Hypertrophic cardiomyopathy patients implanted with a S-ICD had lower 5-year risk of appropriate and inappropriate ICD therapies as well as of major lead-related complications as compared to those implanted with a TV-ICD. Long-term comparative follow-up studies will clarify whether the lower incidence of major lead-related complications will translate into a morbidity or survival benefit.

Для цитирования: Francia Pietro, Ziacchi Matteo, Adduci Carmen, Ammendola Ernesto, Pieragnoli Paolo, De Filippo Paolo, Rapacciuolo Antonio, Rella Valeria, Migliore Federico, Viani Stefano, Musumeci Maria Beatrice, Biagini Elena, Lovecchio Mariolina, Baldini Rossella, Falasconi Giulio, Autore Camillo, Biffi Mauro, Cecchi Franco. Clinical course of hypertrophic cardiomyopathy patients implanted with a transvenous or subcutaneous defibrillator.. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. 2023. DOI: 10.1093/europace/euad270.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.